Drug intelligence / Profile preview

APOSEC

Development stage: Phase 1
Lead developer: Aposcience
Administration: Topical, Intravenous, Intrathecal

Overview

APOSEC is a biopharmaceutical product consisting of a complex mixture of cytokines and other proteins and factors derived from secretomes of white blood cells isolated from peripheral blood. It acts synergistically to provide both anti-inflammatory and pro-angiogenic effects. APOSEC is being developed for conditions where wound healing is impaired or adverse tissue remodeling needs to be prevented.

Beyond the preview

Go deeper on APOSEC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APOSEC.

Explore the full profile